These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 8549168)
1. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168 [TBL] [Abstract][Full Text] [Related]
2. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359 [TBL] [Abstract][Full Text] [Related]
3. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS. Mady EA Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896 [TBL] [Abstract][Full Text] [Related]
4. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852 [TBL] [Abstract][Full Text] [Related]
5. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663 [TBL] [Abstract][Full Text] [Related]
6. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Stieber P; Dienemann H; Hasholzner U; Fabricius PG; Schambeck C; Weinzierl M; Poley S; Samtleben W; Hofmann K; Meier W Int J Biol Markers; 1994; 9(2):82-8. PubMed ID: 7523546 [TBL] [Abstract][Full Text] [Related]
7. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995 [TBL] [Abstract][Full Text] [Related]
8. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612 [TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Plebani M; Basso D; Navaglia F; De Paoli M; Tommasini A; Cipriani A Br J Cancer; 1995 Jul; 72(1):170-3. PubMed ID: 7541234 [TBL] [Abstract][Full Text] [Related]
10. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116 [TBL] [Abstract][Full Text] [Related]
12. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091 [TBL] [Abstract][Full Text] [Related]
13. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117 [TBL] [Abstract][Full Text] [Related]
15. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation. Giovanella L; Ceriani L; Bandera M; Rimoldi R; Beghé B; Roncari G Q J Nucl Med; 1995 Dec; 39(4):285-9. PubMed ID: 8624791 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651 [TBL] [Abstract][Full Text] [Related]
17. How to express tumor markers in bronchoalveolar lavage. Gómez de Terreros Caro FJ; Alvarez-Sala R; Prados MC; Callol L; Gómez de Terreros Sánchez FJ; Villamor J Int J Biol Markers; 2004; 19(1):67-71. PubMed ID: 15077929 [TBL] [Abstract][Full Text] [Related]
18. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers]. Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432 [TBL] [Abstract][Full Text] [Related]
19. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Buccheri G; Torchio P; Ferrigno D Chest; 2003 Aug; 124(2):622-32. PubMed ID: 12907552 [TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Sugama Y; Kitamura S; Kawai T; Ohkubo A; Hasegawa S; Kuriyama T; Kato H; Fukuoka M; Ohkawa J Jpn J Cancer Res; 1994 Nov; 85(11):1178-84. PubMed ID: 7530241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]